BR112023022485A2 - Expansão de linfócitos em um único recipiente - Google Patents

Expansão de linfócitos em um único recipiente

Info

Publication number
BR112023022485A2
BR112023022485A2 BR112023022485A BR112023022485A BR112023022485A2 BR 112023022485 A2 BR112023022485 A2 BR 112023022485A2 BR 112023022485 A BR112023022485 A BR 112023022485A BR 112023022485 A BR112023022485 A BR 112023022485A BR 112023022485 A2 BR112023022485 A2 BR 112023022485A2
Authority
BR
Brazil
Prior art keywords
single container
cells
lymphocytes
lymphocyte expansion
expansion
Prior art date
Application number
BR112023022485A
Other languages
English (en)
Inventor
Alexandre Harari
Florence Salmon
George Coukos
Simone Steiner
Original Assignee
Centre Hospitalier Univ Vaudois Chuv
Ludwig Inst For Cancer Res Ltd
Tigen Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Vaudois Chuv, Ludwig Inst For Cancer Res Ltd, Tigen Pharma Sa filed Critical Centre Hospitalier Univ Vaudois Chuv
Publication of BR112023022485A2 publication Critical patent/BR112023022485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Abstract

expansão de linfócitos em um único recipiente. a presente invenção se refere a uma população de linfócitos compreendendo pelo menos 90% de células t cd3+ e menos de 5% de células b, em que pelo menos 70% da referida porção de células t são viáveis, pelo menos 20% são cd27/cd28 duplamente positivos e menos mais de 10% são triplo positivos para cd45ra, cd57 e klrg1 e um método para expansão de uma população de linfócitos específicos para um ou mais antígenos compreendendo uma única fase de cultura.
BR112023022485A 2021-04-30 2022-04-29 Expansão de linfócitos em um único recipiente BR112023022485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21171565 2021-04-30
PCT/EP2022/061639 WO2022229464A1 (en) 2021-04-30 2022-04-29 Single vessel expansion of lymphocytes

Publications (1)

Publication Number Publication Date
BR112023022485A2 true BR112023022485A2 (pt) 2024-01-09

Family

ID=76034406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022485A BR112023022485A2 (pt) 2021-04-30 2022-04-29 Expansão de linfócitos em um único recipiente

Country Status (8)

Country Link
EP (1) EP4330380A1 (pt)
JP (1) JP2024517793A (pt)
KR (1) KR20240026905A (pt)
CN (1) CN117321189A (pt)
AU (1) AU2022267777A1 (pt)
BR (1) BR112023022485A2 (pt)
CA (1) CA3214450A1 (pt)
WO (1) WO2022229464A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115558641B (zh) * 2022-11-14 2023-05-12 四川新生命干细胞科技股份有限公司 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
BR112015025460B1 (pt) 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
KR102429859B1 (ko) 2013-12-06 2022-08-04 더 브로드 인스티튜트, 인코퍼레이티드 신생물 백신을 위한 제형
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
RU2020132040A (ru) 2015-05-20 2020-10-12 Те Брод Инститьют Инк. Общие неоантигены
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
JP7116061B2 (ja) 2016-08-21 2022-08-09 アドヴァ バイオテクノロジー リミテッド バイオリアクタおよびその使用法
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
JP7357613B2 (ja) * 2017-11-06 2023-10-06 ラディック インスティテュート フォア キャンサー リサーチ リミテッド リンパ球の拡大方法
WO2021116714A1 (en) 2019-12-12 2021-06-17 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
CA3168700A1 (en) 2020-01-20 2021-07-29 Adva Biotechnology Ltd. Device and method for controlling a bioreactor

Also Published As

Publication number Publication date
CN117321189A (zh) 2023-12-29
JP2024517793A (ja) 2024-04-23
AU2022267777A1 (en) 2023-10-05
WO2022229464A1 (en) 2022-11-03
CA3214450A1 (en) 2022-11-03
EP4330380A1 (en) 2024-03-06
KR20240026905A (ko) 2024-02-29

Similar Documents

Publication Publication Date Title
BR112023022485A2 (pt) Expansão de linfócitos em um único recipiente
AR111785A2 (es) Método in vitro de producción de eritrocitos
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
BRPI1008409A2 (pt) cartucho analítico e método para produção do mesmo
BR112018075548A2 (pt) método para estabilizar proteínas
BR112021024657A2 (pt) Célula de bacillus não esporulada, uso da referida célula, oligossacarídeo fucosilado, bem como o método para a produção e uso do mesmo e composição nutricional
BR112022003604A2 (pt) Produção de oligossacarídeos sialilados em células de bacillus
PH12021551037A1 (en) Methods for isolating and expanding cells
BRPI0705239A (pt) sistema de controle de manipulação de documento baseado em retroalimentação
WO2022016166A3 (en) Differentiation of trophectoderm lineage cells from pluripotent stem cells
BR112022016006A2 (pt) Cepas de produção dependentes de carga
BR112022010020A2 (pt) Métodos para configurar indicação de cancelamento de uplink para portadores de uplink suplementários
BR112021020950A2 (pt) Extrato de levedura rico em trealose
BR112023025136A2 (pt) Suporte para conter uma pluralidade de recipientes, peça em bruto para formar um suporte para conter uma pluralidade de recipientes, método para formar um suporte para conter uma pluralidade de recipientes, e embalagem
Omar et al. Application of single step with three generalized hybrid points block method for solving third order ordinary differential equations
BR112023012510A2 (pt) Método para a fabricação de um objeto e folha revestida
WO2022149142A3 (en) Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
BR112023016918A2 (pt) Material derivado de microrganismo e métodos para produzir o mesmo
WO2022047222A3 (en) Crispr/cas9 multiplex knockout of host cell proteins
BR112022008600A2 (pt) Métodos de fermentação de esporos de bacillus recombinantes
AU2018257307A1 (en) Hematopoietic progenitor cell marker
WO2023081412A3 (en) Immune cell populations and uses thereof
BR112023018940A2 (pt) Célula hospedeira geneticamente modificada capaz de produzir vanilina ou glucovanilina, método para produzir vanilina ou glucovanilina, e, vanilina ou glucovanilina
Wang Dynamic behaviors of an amensalism system with density dependent birth rate
BR112021024953A2 (pt) Sistemas e métodos para enchimento de recipiente baseado em força centrífuga